Journal of the American College of Cardiology Vol. 43, No. 12, by the American College of Cardiology Foundation ISSN /04/$30.
|
|
- Beverly Alexander
- 5 years ago
- Views:
Transcription
1 Journal of the American College of Cardiology Vol. 43, No. 12, by the American College of Cardiology Foundation ISSN /04/$30.00 Published by Elsevier Inc. doi: /j.jacc CLINICAL RESEARCH Evaluation of the Effect of Oral on Clinical Outcome and Angiographic Restenosis After Percutaneous Coronary Intervention The Randomized, Double-Blind, -Controlled, Multicenter Slow-Release for Prevention of Cardiovascular Events After Angioplasty (VESPA) Trial Hans-Peter Bestehorn, MD,* Franz-Josef Neumann, MD,* Heinz Joachim Büttner, MD,* Peter Betz, MD, PHD,* Peter Stürzenhofecker, MD, Eberhard von Hodenberg, MD, Antoine Verdun, MD, Laszlo Levai, MD, Jean Pierre Monassier, MD, Helmut Roskamm, MD* Bad Krozingen, Bad Neustadt, and Lahr, Germany; and Colmar and Mulhouse, France Clinical Trials OBJECTIVES BACKGROUND METHODS RESULTS CONCLUSIONS We investigated the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention (PCI). Thus far, there is no established systemic pharmacologic approach for the prevention of restenosis after PCIs. Five small studies reported encouraging results for calcium channel blockers. Our randomized double-blind trial included 700 consecutive patients with successful PCI of a native coronary artery. Patients received the calcium channel blocker verapamil, 240 mg twice daily for six months, or placebo. Primary clinical end point was the composite rate of death, myocardial infarction, and target vessel revascularization (TVR) during one-year follow-up; the angiographic end point was late lumen loss at the six-month follow-up angiography. We obtained complete clinical follow-up in 95% of the patients, and scheduled angiography was performed in 94%. The proportion of patients treated with stents was 83%. The primary clinical end point was reached in 67 (19.3%) patients on verapamil and in 103 (29.3%) patients on placebo (relative risk [RR] 0.66 [95% confidence interval (CI) 0.48 to 0.89]; p 0.002). This difference between the groups was driven by TVR (17.5% with verapamil vs. 26.2% with placebo; RR 0.67 [95% CI 0.49 to 0.93]; p 0.006). Late lumen loss was mm with verapamil and mm with placebo (p 0.11). Compared with placebo, verapamil reduced the rate of restenosis 75% (7.8% vs. 13.7%; RR 0.57 [95% CI 0.35 to 0.92]; p 0.014). compared with placebo improves long-term clinical outcome after PCI of native coronary arteries by reducing the need for TVR. This was caused by a reduction in the rate of high-grade restenosis. (J Am Coll Cardiol 2004;43:2160 5) 2004 by the American College of Cardiology Foundation The long-term benefit from percutaneous coronary interventions (PCI) is limited by restenosis (1). Despite intensive research in recent years, it is still controversial whether any systemic drug therapy can prevent this adverse outcome. To this end, various drugs with promising efficacy in animal experiments have been tested in patients. Yet, most of the studies failed to show an unequivocal beneficial effect of systemic drug therapy on restenosis. There is reasonable skepticism whether systemic administration can achieve the local drug levels needed to suppress restenosis (2 4). Calcium channel blockers are among the few drugs with promising results in the prevention of restenosis. The From the *Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany; Herz-und Gefäßklinik Bad Neustadt, Bad Neustadt, Germany; Herz-Zentrum Lahr, Lahr, Germany; Clinic St. Joseph Colmar, Colmar, France; and Hospital Emil Müller, Mulhouse, France. Supported, in part, by a grant from Abbott GmbH & Co., KG Ludwigshafen, Germany. Manuscript received May 7, 2003; revised manuscript received January 2, 2004, accepted February 10, putative antirestenotic properties of calcium channel blockers have been attributed to concentration-dependent inhibition of smooth muscle cell transformation and proliferation after stimulation with platelet-derived growth factor (5 7). Meta-analysis (8) of five small studies (9 13) yielded a significant 30% relative reduction in the risk of restenosis by calcium channel blockers as compared with placebo. This finding, however, has not been tested in an adequately powered trial. Therefore, we conducted the multicenter, randomized, double-blind, placebo-controlled, Slow-Release for Prevention of cardiovascular Events After Angioplasty (VESPA) trial to assess the effect of the calcium channel blocker verapamil on clinical outcome and angiographic restenosis after PCI. METHODS Patients selection and stent placement. Patients of age 35 and 80 years with successful PCI of a native coronary
2 JACC Vol. 43, No. 12, 2004 June 16, 2004: Bestehorn et al. Oral and Restenosis After PCI 2161 Abbreviations and Acronyms CABG coronary artery bypass grafting CAD coronary artery disease CI confidence interval MI myocardial infarction MLD minimal lumen diameter PCI percutaneous coronary intervention PTCA percutaneous transluminal coronary angioplasty RR relative risk TVR target vessel revascularization VESPA Slow-Release for Prevention of Cardiovascular Events After Angioplasty trial artery were eligible for the study. Successful intervention was defined by residual stenosis 30% on visual estimation and in case of stenting desired position of stent. We excluded patients with restenotic lesions, occlusions, lesions in bypass grafts, and left main location as well as patients with unstable angina, acute myocardial infarction (MI), ad-hoc and multistage PCI, insulin-dependent diabetes, renal insufficiency, sick sinus syndrome, atrioventricular node block, congestive heart failure and/or left ventricular ejection fraction 40%, severe concomitant diseases, contraindications to verapamil, and patients with inability to provide informed consent for participation. The study was approved by the institutional ethical review board of each hospital, and all patients gave written informed consent before inclusion in the study. Although the use of stents was encouraged, the percutaneous treatment modality was left to the operator s discretion. All patients received aspirin 100 mg, once daily, indefinitely and, in case of stenting, ticlopidine 250 mg, twice daily, or clopidogrel 75 mg, once daily, for four weeks. Thienopyridines were started immediately after the intervention. Study protocol. We designed our study as a prospective, multicenter, randomized, double-blind, placebo-controlled trial. Within 30 min after PCI, we assigned eligible patients to receive either verapamil, 240 mg slow-release tablets, or identical-appearing placebo twice daily. At each participating center, allocation to the study treatment was based on computer-generated random numbers that were used for double-blind labeling. In patients undergoing multivessel PCI (n 83), the most clinically relevant lesion was defined as the study lesion at the time of randomization. The study drug was started immediately after PCI and was continued until three days before six-month follow-up angiography. After PCI, we determined plasma concentrations of creatine kinase and its MB isoenzyme systematically for 48 h. We scheduled outpatient visits at one and three months after randomization for clinical follow-up including 12-lead electrocardiogram recordings. Patients returned to the hospital for routine angiographic restudy and clinical evaluation including bicycle ergometry at six months. Follow-up angiography was performed earlier if the patient had recurrent symptoms or signs of ischemia. Patients who had undergone angiography at 4 months after recruitment without meeting the criteria for a clinical end point were encouraged to undergo repeat angiography at six months. At each follow-up visit, we assessed compliance by pill counts. Quantitative angiography. Angiographic images were stored on compact discs (one center) or grabbed from cine films (other centers) and analyzed before the study was unblinded. Quantitative analysis was performed as described previously (14 16). Using the same two orthogonal views throughout the study, we obtained minimal luminal diameter (MLD), reference diameter, percent diameter stenosis, and the diameter of the maximally inflated balloon from the analysis system (Cardiovascular Angiographic Analysis System, Department of Medical Informatics, University of Limburg, Limburg, the Netherlands). Acute gain was calculated as the difference between post-stenting and predilation MLD, late loss as the difference between post-stenting MLD and MLD at follow-up, net gain as the difference between MLD at follow-up, and predilation MLD and loss index was calculated as the ratio of late loss to acute gain. All measurements were performed by the same blinded operator; intraobserver variability was 0.10 mm for MLD and 2.58% for diameter stenosis. Study end points. Our clinical primary end point was the combined incidence of death, MI, and target vessel revascularization (TVR). Myocardial infarction was defined as the presence of new Q waves ( 40 ms) in two or more contiguous electrocardiographic leads or an elevation of creatine kinase or its MB isoenzyme to at least 3 the upper limit of normal (80 U/l, 10 U/l, respectively) in two samples during hospitalization or to 2 the upper limit of normal after discharge. We defined TVR as coronary artery bypass surgery or repeat percutaneous angioplasty involving the treated vessel and performed for symptoms or signs of ischemia in the presence of angiographic restenosis ( 50%). Target vessel revascularization by coronary artery bypass surgery, which was indicated at the time of follow-up angiography, was counted as an event, even when performed during subsequent hospital admission. As our primary angiographic end point, we assessed late loss. We also analyzed other angiographic indexes of restenosis, including loss index, percent diameter stenosis, and the incidence of severe restenosis, defined as diameter stenosis 75%. Sample size estimation and statistical analysis. For calculation of sample size, we assumed a 25% incidence of our primary clinical end point (17). We designed the study to have a power of 80% to detect a 40% reduction in our primary clinical end point by verapamil as compared with placebo with a two-sided alpha value of According to these assumptions, 325 patients were required in each treatment arm. To account for losses to follow-up, we intended to include 700 patients. Assuming a normal distribution with a standard deviation of 0.5 mm for late loss (17) and allowing for missing angiograms in 100 patients,
3 2162 Bestehorn et al. JACC Vol. 43, No. 12, 2004 Oral and Restenosis After PCI June 16, 2004: Table 1. Baseline Demographic and Clinical Characteristics of the Study Cohort (n 352) p Value Age (yrs) Women 59 (17.0) 65 (18.5) 0.60 BMI (kg/m 2 ) Active smoker 74 (21.3) 84 (23.9) 0.41 Family history of CAD 122 (35.1) 128 (36.4) 0.72 Hypercholesterolemia 278 (79.9) 285 (81.0) 0.72 Hypertension 219 (62.9) 217 (61.6) 0.73 Diabetes 49 (14.1) 45 (12.9) 0.62 Multivessel disease 167 (48.0) 158 (44.9) 0.41 Previous balloon angioplasty 44 (12.6) 39 (11.1) 0.52 Previous coronary bypass 9 (2.6) 15 (4.3) 0.22 operation Previous myocardial infarction 115 (33.1) 120 (34.1) 0.77 Data are expressed as mean value SD or number of patients (%). BMI body mass index; CAD coronary artery disease. Figure 1. Trial profile. PCI percutaneous catheter intervention. this sample size gave us an 80% power to detect a 0.13 mm difference in late loss with a two-sided alpha value of All analyses were performed according to the intentionto-treat principle. Data are presented as mean SD or as counts or proportions. We assessed differences between the groups with use of a two-sided chi-square test for categorical variables. For continuous variables we used the unpaired t test. A value of p 0.05 in the two-tailed test was considered to statistically significant. The impact of baseline characteristics and other pertinent covariables on the primary clinical end point was adjusted using multivariate logistic regression. To account for the double primary end point, we adjusted the level of significance for our primary end points to p For all statistical analyses, we used SAS 6.12 software package (SAS Institute, Cary, North Carolina). RESULTS Study cohort and follow-up. The trial population is shown in Figure 1. The study enrolled 700 patients; 348 were assigned to verapamil and 352 to placebo. A coronary stent was placed in 581 patients (83%). The study groups were homogeneous with respect to baseline demographic, clinical, and angiographic characteristics (Tables 1 to 3). Thirty-seven patients were lost to clinical follow-up, and five additional patients refused second angiography. Thirteen patients of the verapamil group and 33 patients of the placebo group underwent follow-up angiography prematurely. Of the patients on verapamil, 19.5% (68 of 348) discontinued their study medication because of constipation (n 23), second- or a third-degree heart block (n 8), or other cardiovascular side effects (n 37). In the placebo group, the discontinuation rate was 15.6% (55 of 352). In addition, 11.8% (n 41) of the verapamil group and 10.8% (n 38) of the placebo group had a pill count that differed by more than 30% from the expected pill count. Clinical events. The primary clinical end point was reached in 19.3% (67 of 348) of the verapamil group and in 29.3% (103 of 352) of the placebo group (Table 4). Thus, adverse cardiac events were significantly (p 0.002) fewer in the verapamil group than in the placebo group with a relative risk (RR) reduction by verapamil of 34% (Table 4). The difference in the incidence of our primary end point was driven by a reduction in TVRs (Table 4). There were no appreciable differences in the incidences of death or MI. The risk reduction for the TVR by verapamil as compared with placebo was similar in patients receiving a stent and in patients treated with plain percutaneous transluminal coronary angioplasty (PTCA): (RR, 0.74 [95% confidence Table 2. Medication at Discharge (n 352) p Value Aspirin 338 (97.1) 342 (97.2) 0.98 Thienopyridines 297 (85.3) 305 (86.6) 0.62 Nitrates 174 (50.0) 160 (45.5) 0.23 CSE inhibitors 239 (68.7) 248 (70.5) 0.61 ACE inhibitors 153 (44.0) 156 (44.3) 0.93 AT-II receptor blockers 9 (2.6) 10 (2.8) 0.84 Diuretics 26 (7.5) 35 (9.9) 0.25 Data are expressed as number of patients (%). ACE angiotensin-converting enzyme; AT-II angiotensin-ii; CSE cholesterol synthesis enzyme.
4 JACC Vol. 43, No. 12, 2004 June 16, 2004: Bestehorn et al. Oral and Restenosis After PCI 2163 Table 3. Baseline Angiographic and Procedural Characteristics of the Study Cohort (n 352) p Value Complex lesions (AHA/ACC type B2, C) 169 (48.6) 169 (48.0) 0.94 Lesions per patient Vessel size, mm Before PCI MLD, mm Diameter stenosis, % Procedural variables Balloon-to-vessel ratio Inflation pressure, atm Stent placement 290 (83.3) 291 (82.7) 0.82 In-stented patients: Number of stents per stented study lesion Stented length, mm After PCI MLD, mm Acute gain (mm) Diameter stenosis, % Data are expressed as mean value SD or number of patients (%). AHA/ACC American Heart Association/American College of Cardiology; MLD minimum luminal diameter; PCI percutaneous coronary intervention. interval (CI) 0.52 to 1.05]; p 0.05 vs. RR 0.50 [95% CI 0.21 to 1.15]; p 0.06). In a multivariable logistic regression model that took into account baseline variables listed in Tables 1 and 3, the adjusted odds ratio was 0.52 (95% CI 0.32 to 0.84; p 0.007) for the clinical primary end point comparing both treatment strategies. Angiographic indexes of restenosis. Mean late loss was mm in the verapamil group and mm in the placebo group (Table 5); thus, our primary angiographic end point did not reach statistical significance (p 0.11). The cumulative distribution of percent diameter stenosis at follow-up (Fig. 2) shows a separation of the curves in the region of more severe stenoses. Accordingly, we found a significant reduction in the rate of high-grade restenosis ( 75%) by verapamil as compared with placebo, but only a trend towards a reduction in restenosis rate according to the 50% criterion (Table 5). Other indices of restenosis confirmed the trend towards attenuated restenosis by verapamil, but did not reach statistical significance either. The differences in late loss between the verapamil and placebo groups were similar after stenting ( mm vs mm; p 0.20) and after plain balloon angioplasty ( mm vs mm; p 0.67), as were the risk reductions for high-grade restenosis (RR 0.56 [95% CI 0.33 to 0.97]; p 0.03 vs. RR 0.58 [95% CI 0.12 to 1.75]; p 0.30). DISCUSSION Our randomized, placebo-controlled multicenter trial investigated the effect of verapamil on the clinical and angiographic outcome after PCI., administered for six months after PCI, reduced the incidence of major adverse cardiac events, our primary clinical end point, by reducing the need for repeat TVR. Consistent with this outcome, we found a significant reduction in the incidence of high-grade restenosis, although our primary angiographic end point, late loss, failed to show significant differences. Previous trials on calcium channel blockers were flawed by small sizes and methodological issues, such as subjective evaluation of restenosis. To our knowledge, our trial is the first adequately powered study addressing the effect of verapamil on restenosis with the use of quantitative coronary angiography. Although the impact of verapamil on restenosis was con- Table 4. Clinical Events (n 352) p Value RR (95% CI) Any cardiac event 67 (19.3) 103 (29.3) ( ) Death or MI 6 (1.7) 11 (3.1) ( ) Death 2 (0.6) 1 (0.3) ( ) Nonfatal MI 4 (1.2) 10 (2.8) ( ) TVR 61 (17.5) 92 (26.2) ( ) PCI 58 (16.7) 87 (24.8) ( ) CABG 3 (0.9) 5 (1.4) ( ) Data are expressed as number of patients (%). CABG coronary artery bypass grafting; MI myocardial infarction; PCI percutaneous coronary intervention; RR relative risk; TVR target vessel revascularization; CI confidence interval.
5 2164 Bestehorn et al. JACC Vol. 43, No. 12, 2004 Oral and Restenosis After PCI June 16, 2004: Table 5. Quantitative Angiographic Data at Angiographic Follow-Up (n 321) (n 335) RR (95% CI) p Value Late loss, mm MLD, mm Diameter stenosis, % Loss index Net gain, mm Diameter stenosis 50% 82 (25.7) 108 (32.3) 0.79 ( ) 0.06 Diameter stenosis 75% 25 (7.8) 46 (13.7) 0.57 ( ) Data are expressed as numbers (percentages) or mean value SD. Abbreviations as in Tables 3 and 4. siderably smaller than anticipated based on the earlier studies, the principle effect is confirmed. With the weight of the present study, currently available evidence suggests that calcium antagonists are capable of interfering with mechanisms involved in restenosis formation. Mechanisms that could be targeted by calcium antagonists include smooth muscle cell transformation, and migration and proliferation, as well as elaboration of extracellular matrix proteins (18 20). Our analyses, specifically the cumulative distributions of percent diameter stenosis, suggest a predominant effect of verapamil in the prevention of excessive restenosis formation. Previous studies revealed a bimodal distribution of restenosis formation after plain PTCA and after stenting (21). This bimodal distribution delineates two populations, which develop distinctively different degrees of lumen renarrowing. From our findings, it is conceivable that verapamil acts predominantly on the population with the strongest propensity to renarrowing. In this population, the antiproliferative properties of verapamil that have been described in experimental studies may become particularly effective. Study limitations. Of a large number of patients screened, only 6% were eventually included in the study. This was largely due to the strict inclusion criteria avoiding high-risk patients such as those with acute coronary syndromes and patients who were unlikely to complete follow-up (Fig. 1). Notably, only 2.1% were excluded because of contraindications to verapamil. On the other hand, the dosage of verapamil had to be reduced or withdrawn in about onethird of the patients. The possibility has to be considered that the reduction in TVR was caused by the antianginal properties of verapamil. To reduce this effect, the study protocol mandated bicycle ergometry before follow-up angiography and after discontinuation of study medication for three days. Nevertheless, the role of antianginal properties of verapamil cannot be completely ruled out. Although the majority of our patients were treated with stents, there was some admixture from patients who underwent plain PTCA. The mechanisms of restenosis differ substantially between the two treatment modalities. Neointima formation accounts for about 90% of the lumen loss after stenting (22,23). After plain PTCA, neointima formation is less pronounced, and about twothirds of lumen loss are caused by early elastic recoil and late vessel shrinkage. We cannot assume a uniform action of verapamil on each of these mechanisms. The low number of patients treated with plain PTCA prevented the detection of differences between the two percutaneous treatment modalities, but may have contributed to scatter. Clinical implications. Although the effect of verapamil on restenosis formation was statistically detectable, its extent was limited and has to be weighed against the disadvantages of withholding beta-blockers. In the meantime, stents releasing antiproliferative agents have proven, by far, to be more powerful tools in the prevention of restenosis (24). However, these devices are costly, and there is concern that the impairment of vascular healing processes after intervention might pose a substantial risk of late thrombotic events (25). Therefore, there is continued interest in the search for alternative approaches (26). To this end, the results of our study demonstrate the potential that resides in systemic administration of antiproliferative agents. Reprint requests and correspondence: Dr. Hans-Peter Bestehorn, Herz-Zentrum Bad Krozingen, Südring 15, Bad Krozingen, Germany. hans-peter.bestehorn@herzzentrum.de. REFERENCES Figure 2. Cumulative distribution curves for percent diameter stenosis at follow-up in the two treatment groups. 1. McBride W, Lange RA, Hillis LD. Restenosis after successful coronary angioplasty: pathophysiology and prevention. N Engl J Med 1988;318:
6 JACC Vol. 43, No. 12, 2004 June 16, 2004: Bestehorn et al. Oral and Restenosis After PCI Von Hodenberg E, Tost B, Scheffold T. New strategies in the treatment of restenosis. Z Kardiol 2000;89 Suppl 7: Garza L, Aude YW, Saucedo JF. Can we prevent in-stent restenosis? Curr Opin Cardiol 2002;17: Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet 2003;361: Jackson CL, Bush RC, Bowyer DE. Inhibitory effect of calcium antagonists on balloon catheter-induced arterial smooth muscle cell proliferation and lesion size. Atherosclerosis 1988;69: Block LH, Emmons LR, Vogt E, et al. Ca2 -channel blockers inhibit the action of recombinant platelet-derived growth factor in vascular smooth muscle cells. Proc Natl Acad Sci USA 1989;7: Thaulow E. Pharmacologic effects of calcium channel blockers on restenosis. J Cardiovasc Pharmacol 1999;33 Suppl 2: Hillegass WB, Ohman EM, Leimberger JD, et al. A meta-analysis of randomised trials of calcium antagonists to reduce restenosis after coronary angioplasty. Am J Cardiol 1994;73: Corcos T, David PR, Val PG, et al. Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1985;109: Withworth HB, Roubin GS, Hollman J, et al. Effect of nifedipin on recurrent stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1986;8: O Keefe JH, Giorgi LV, Hartzler GO, et al. Effects of diltiazem on complications and restenosis after coronary angioplasty. Am J Cardiol 1991;67: Unverdorben M, Kunkel B, Leucht M, et al. Reduction of restenosis after PTCA by diltiazem? Circulation 1992;86 Suppl 1: Hoberg E, Dietz R, Frees U, et al. treatment after coronary angioplasty in patients at high risk of recurrent stenosis. Br Heart J 1994;71: Bestehorn HP, Rensing UF, Roskamm H, et al. The effect of simvastatin on progression of coronary artery disease: the multicenter Coronary Intervention study (CIS). Eur Heart J 1997;18: Frey AW, Hodgson JM, Muller C, et al. Ultrasound-guided strategy for provisional stenting with focal balloon combination catheter: results from the randomized Strategy for Intracoronary ultrasoundguided PTCA and Stenting (SIPS) trial. Circulation 2000;102: Reiber JH, Serruys PW, Kooijman CJ. Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms. Circulation 1985;71: Karsch KR, Preisack MB, Baildon R, et al. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty: results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and - Controlled Evaluation. J Am Coll Cardiol 1996;28: Hoberg E. The effects of calcium antagonists after PTCA. Eur Heart J 1995;16 Suppl H: Pepine CJ. The role of calcium antagonists in ischemic heart disease. Eur Heart J 1995;16 Suppl H: Thaulow E. Pharmacologic effects of calcium channel blockers on restenosis. J Cardiovasc Pharmacol 1999;33 Suppl 2: Schomig A, Kastrati A, Elezi S, et al. Bimodal distribution of angiographic measures of restenosis six months after coronary stent placement. Circulation 1997;96: Nakatani M, Takeyama Y, Shibata M, et al. Mechanisms of restenosis after coronary intervention: difference between plain old balloon angioplasty and stenting. Cardiovasc Pathol 2003;12: Schwartz RS, Henry TD. Pathophysiology of coronary artery restenosis. Rev Cardiovasc Med 2002;3 Suppl 5:S Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet 2003;18:361: Liistro F, Colombo A. Late acute thrombosis after paclitaxel eluting stent implantation. Heart 2001;86: Farb A, John M, Acampado E, et al. Oral everolimus inhibits in-stent neointimal growth. Circulation 2002;106:
A Randomized Comparison of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin After the Placement of Coronary Artery Stents
Journal of the American College of Cardiology Vol. 41, No. 6, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02974-1
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationInfluence of Planned Six-Month Follow-Up Angiography on Late Outcome After Percutaneous Coronary Intervention A Randomized Study
Journal of the American College of Cardiology Vol. 38, No. 4, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01476-0 Influence
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationJournal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.039
More informationJournal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL
More informationA Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES.
A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES ISAR-TEST 2 Trial Robert A. Byrne, MB MRCPI Deutsches Herzzentrum and 1. Med.
More informationSupplementary Material to Mayer et al. A comparative cohort study on personalised
Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationJournal of the American College of Cardiology Vol. 47, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 47, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.05.102
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationClinical Investigations
Clinical Investigations Clinical Outcomes for Single Stent and Multiple Stents in Contemporary Practice Qiao Shu Bin, MD; Liu Sheng Wen, MD; Xu Bo, BS; Chen Jue, MD; Liu Hai Bo, MD; Yang Yue Jin, MD; Chen
More information2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular
More informationJournal of the American College of Cardiology Vol. 39, No. 8, by the American College of Cardiology Foundation ISSN /02/$22.
Journal of the American College of Cardiology Vol. 39, No. 8, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)01774-6
More informationCoronary Artery Disease: Revascularization (Teacher s Guide)
Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention
More informationLink between effectiveness and cost data Costing was conducted prospectively on the same patient sample as that used in the effectiveness analysis.
Heparin after percutaneous intervention (HAPI): a prospective multicenter randomized trial of three heparin regimens after successful coronary intervention Rabah M, Mason D, Muller D W, Hundley R, Kugelmass
More information1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES
1 Comparison of Ischemic and Bleeding Events After Drug- Eluting Stents or Bare Metal Stents in Subjects Receiving Dual Antiplatelet Therapy: Results from the Randomized Dual Antiplatelet Therapy (DAPT)
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationJournal of the American College of Cardiology Vol. 46, No. 5, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 46, No. 5, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.06.009
More informationThree-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB
More informationImpact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease
Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease Gjin Ndrepepa, Tomohisa Tada, Massimiliano Fusaro, Lamin King, Martin Hadamitzky,
More informationAngiographic and Intravascular Ultrasound Predictors of In-Stent Restenosis
1630 JACC Vol. 32, No. 6 Angiographic and Intravascular Ultrasound Predictors of In-Stent Restenosis SHUNJI KASAOKA, MD, JONATHAN M. TOBIS, MD, FACC, TATSURO AKIYAMA, MD,* BERNHARD REIMERS, MD,* CARLO
More informationPathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL
Pathology of percutaneous interventions (PCI) in coronary arteries Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL Percutaneous Coronary Intervention (PCI) Definition: transcatheter opening of
More informationLessons learned From The National PCI Registry
Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients
More informationJMSCR Vol 07 Issue 01 Page January 2018
www.jmscr.igmpublication.org Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v7i1.109 Short Term Outcome in a Severe Coronary Artery Disease with
More informationRestenosis, Reocclusion and Adverse Cardiovascular Events After Successful Balloon Angioplasty of Occluded Versus Nonoccluded Coronary Arteries
JACC Vol. 27, No. 1 1 January 1996:1-7 CLINICAL STUDIES INTERVENTIONAL CARDIOLOGY Restenosis, Reocclusion and Adverse Cardiovascular Events After Successful Balloon Angioplasty of Occluded Versus Nonoccluded
More informationCurrent PTCA practice and clinical outcomes in the Netherlands: the real world in the pre-drug-eluting stent era
3 Current PTCA practice and clinical outcomes in the Netherlands: the real world in the pre-drug-eluting stent era Pascalle S. Monraats, Willem R.P. Agema, Aeilko H. Zwinderman, Robbert J. de Winter, René
More informationInter-regional differences and outcome in unstable angina
European Heart Journal (2000) 21, 1433 1439 doi:10.1053/euhj.1999.1983, available online at http://www.idealibrary.com on Inter-regional differences and outcome in unstable angina Analysis of the International
More informationPCI for Left Anterior Descending Artery Ostial Stenosis
PCI for Left Anterior Descending Artery Ostial Stenosis Why do you hesitate PCI for LAD ostial stenosis? LAD Ostial Lesion Limitations of PCI High elastic recoil Involvement of the distal left main coronary
More informationRelationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome
Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João
More informationCase Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)?
Cronicon OPEN ACCESS CARDIOLOGY Case Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)? Valentin Hristov* Department of Cardiology, Specialized
More informationTCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI
Indian TUXEDO Trial In Medically Treated Diabetics Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Executive Director and Dean Escorts Heart Institute & Medical Research Center and Fortis Hospitals, New Delhi
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial
ARMYDA-RECAPTURE ( for Reduction of MYocardial Damage during Angioplasty) trial Prospective, multicenter, randomized, double blind trial investigating efficacy of atorvastatin reload in patients on chronic
More informationClinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center
Aging Research Volume 2013, Article ID 471026, 4 pages http://dx.doi.org/10.1155/2013/471026 Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at
More informationSafety and Efficacy of Coronary Stent Implantation. Acute and Six Month Outcomes of 1,126 Consecutive Patients Treated in 1996 and 1997
Original Article Safety and Efficacy of Coronary Stent Implantation. Acute and Six Month Outcomes of 1,126 Consecutive Patients Treated in 1996 and 1997 Luiz Alberto Mattos, Ibraim Pinto, Alexandre Abizaid,
More informationCoronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy
Coronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy Takayuki Ohno, MD, Shinichi Takamoto, MD, Noboru Motomura, MD, Minoru Ono,
More informationThe MAIN-COMPARE Registry
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationConflict of interest :None. Meta-analysis. Zhangwei Chen, MD
Meta-analysis Addition of Cilostazol to Conventional Dual Antiplatelet Therapy Reduces the Risk of Cardiac Events and Restenosis after Drug-Eluting Stent Implantation Zhangwei Chen, MD Department of Cardiology,
More informationIn-Ho Chae. Seoul National University College of Medicine
The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering
More informationBioabsorbable Scaffolding: Technology and Clinical Update. PD Dr. Nicolas Diehm, MD, FESC Inselspital, University Hospital Bern, Switzerland
Bioabsorbable Scaffolding: Technology and Clinical Update PD Dr. Nicolas Diehm, MD, FESC Inselspital, University Hospital Bern, Switzerland Disclosures I am not Ron Waksman 1 Clinical experience with AMS
More informationAngiographic long-term results after implantation of the paclitaxel-eluting coronary stent coroflex please : Data under real-world conditions
244 U. Gerk, B. Leithäuser, U. Schäfer, F. Jung, J.-W. Park Applied Cardiopulmonary Pathophysiology 14: 244-249, 2010 Angiographic long-term results after implantation of the paclitaxel-eluting coronary
More informationResults of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions (Long WRIST) Studies
Intracoronary Radiation Therapy Improves the Clinical and Angiographic Outcomes of Diffuse In-Stent Restenotic Lesions Results of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions
More informationCost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study Bagust A, Grayson A D, Palmer N D, Perry R A, Walley T
Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study Bagust A, Grayson A D, Palmer N D, Perry R A, Walley T Record Status This is a critical abstract of an economic
More informationPredictors of 6-Month Angiographic Restenosis inside Bare-Metal Stent in Chinese Patients with Coronary Artery Disease
Original Article Acta Cardiol Sin 2009;25:1 6 Coronary Artery Disease Predictors of 6-Month Angiographic Restenosis inside Bare-Metal Stent in Chinese Patients with Coronary Artery Disease Yung-Lung Chen,
More informationKorea University Guro Hospital, Seoul, Korea * Chonnam National University Hospital, Gwangju, Korea
Left Main Disease versus Non Left Main Disease in Acute Myocardial Infarction Patients in Real world Clinical Practice : Lessons from Korea Acute Myocardial Infarction Registry (KAMIR) Seung-Woon Rha*,
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 6: , 2013
840 Identification of independent risk factors for restenosis following bare metal stent implantation: Role of bare metal stents in the era of drug eluting stents CHANG BUM PARK 1 and HOON KI PARK 2 1
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationJournal of the American College of Cardiology Vol. 37, No. 2, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01133-5 Coronary
More informationSKG Congress, 2015 EVOLVE II. Stephan Windecker
SKG Congress, 2015 EVOLVE II Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland BIODEGRADABLE POLYMER DES Stefanini,
More informationLow fractional diastolic pressure in the ascending aorta increased the risk of coronary heart disease
(2002) 16, 837 841 & 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Low fractional diastolic pressure in the ascending aorta increased the risk
More informationRandomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction
Randomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction The Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4
More informationAdjunctive Stent Implantation Following Directional Coronary Atherectomy in Patients With Coronary Artery Disease
JACC Vol. 32, No. 7 December 1998:1855 60 1855 Adjunctive Stent Implantation Following Directional Coronary Atherectomy in Patients With Coronary Artery Disease EZIO BRAMUCCI, MD,* LUIGI ANGOLI, MD,* PIERA
More informationAre Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &
Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) & Biomatrix TM Single Center Experience (Indonesia)(Final 5 Yr F up) T. Santoso University of
More informationProlonged Oral Morphine Therapy for Severe Angina Pectoris
Vol. 19 No. 5 May 2000 Journal of Pain and Symptom Management 393 Clinical Note Prolonged Oral Morphine Therapy for Severe Angina Pectoris Meir Mouallem, MD, Eli Schwartz, MD, and Zvi Farfel, MD Department
More informationCoronary Artery Stenosis. Insight from MAIN-COMPARE Study
PCI for Unprotected Left Main Coronary Artery Stenosis Insight from MAIN-COMPARE Study Young-Hak Kim, MD, PhD Cardiac Center, University of Ulsan College of Medicine, Asan Medical Center Current Practice
More informationUnprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy
Unprotected Left Main Stenting: Patient Selection and Recent Experience Alaide Chieffo S. Raffaele Hospital, Milan, Italy Class IIa (Level B) AHA/ACC 2005 Guidelines Left Main CAD The use of PCI for pts
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationSurgery Grand Rounds
Surgery Grand Rounds Coronary Artery Bypass Grafting versus Coronary Artery Stenting Charles Ted Lord, R1 Coronary Artery Disease Stenosis of epicardial vessels Metabolic & hematologic Statistics 500,000
More informationINDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT...
May 2017 INDEX 1 INTRODUCTION... 2 2 DEVICE DESCRIPTION... 3 ANTI-PROLIFERATIVE DRUG - SIROLIMUS... 3 BIODEGRADABLE POLYMERS... 3 SIROLIMUS CONTROLLED ELUTION... 4 STENT PLATFORM... 4 3 CLINICAL PROGRAM...
More informationSeQuent Please World Wide Registry
Journal of the American College of Cardiology Vol. 6, No. 18, 212 212 by the American College of Cardiology Foundation ISSN 735-197/$36. Published by Elsevier Inc. http://dx.doi.org/1.116/j.jacc.212.7.4
More informationOUTCOMES WITH LONGTERM DUAL ANTIPLATELET THERAPY AFTER CORONARY ANGIOPLASTY Ashok Kumar Arigonda, K. Nagendra Prasad, O. Hareesh, R.
INDIAN JOURNAL OF CARDIOVACULAR DIEAE JOURNAL in women (IJCD) 016 VOL 1 IUE 3 ORIGINAL ARTICLE 1 OUTCOME WITH LONGTERM DUAL ANTIPLATELET THERAPY AFTER CORONARY ANGIOPLATY Ashok Kumar Arigonda, K. Nagendra
More informationSafety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell
More informationResolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program Prof. Ran Kornowski, MD, FESC, FACC Director - Division of Interventional Cardiology Rabin Medical Center and Tel Aviv University,
More informationC. W. Hamm, B. Cremers, H. Moellmann, S. Möbius-Winkler, U. Zeymer, M. Vrolix, S. Schneider, U. Dietz, M. Böhm, B. Scheller
Paclitaxel-Eluting PTCA-Balloon in Combination with the Coroflex Blue Stent vs the Sirolimus Coated Cypher Stent in the Treatment of Advanced Coronary Artery Disease C. W. Hamm, B. Cremers, H. Moellmann,
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationSafety and Efficacy of Angioplasty with Intracoronary Stenting in Patients with Unstable Coronary Syndromes. Comparison with Stable Coronary Syndromes
Original Article Safety and Efficacy of Angioplasty with Intracoronary Stenting in Patients with Unstable Coronary Syndromes. Comparison with Stable Coronary Syndromes Luís C. L. Correia, José Carlos Brito,
More informationSupplementary Online Content
Supplementary Online Content Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationPatient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
More informationDISRUPT CAD. Todd J. Brinton, MD Clinical Associate Professor of Medicine Adjunct Professor of Bioengineering Stanford University
DISRUPT CAD A multicenter, prospective, single-arm study of percutaneous Lithoplasty prior to stent implantation in heavily calcified coronary lesions Todd J. Brinton, MD Clinical Associate Professor of
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationNEW INTERVENTIONAL TECHNOLOGIES
by Lawrence M Prescott, PhD NEW INTERVENTIONAL TECHNOLOGIES EXPAND TREATMENT OPTIONS FOR CARDIOVASCULAR DISEASE Novel interventional techniques are proving to be of particular value in the treatment of
More informationContemporary Percutaneous Coronary Intervention Versus Balloon Angioplasty for Multivessel Coronary Artery Disease
Contemporary Percutaneous Coronary Intervention Versus Balloon Angioplasty for Multivessel Coronary Artery Disease A Comparison of the National Heart, Lung and Blood Institute Dynamic Registry and the
More informationTreating In-Stent Restenosis with Brachytherapy: Does it Actually Work?
Treating In-Stent Restenosis with Brachytherapy: Does it Actually Work? Matthew T. Menard, M.D. Brigham and Women s Hospital Pacific Northwest Endovascular Conference June 15, 2018 DISCLOSURE Matthew Menard,
More informationJournal of the American College of Cardiology Vol. 46, No. 8, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 46, No. 8, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.06.070
More informationAbciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI. ISAR-REACT 4 Trial
Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI ISAR-REACT 4 Trial Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität, Munich, Germany On behalf of F.-J.
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationJames M. Kirshenbaum, MD, FACC
James M. Kirshenbaum, MD, FACC Associate Professor of Medicine Harvard Medical School Co-Director, Clinical Cardiology Director, Acute Interventional Cardiology Brigham and Women s Hospital Boston, MA
More informationControversies in Cardiac Surgery
Controversies in Cardiac Surgery 3 years after SYNTAX : Percutaneous Coronary Intervention for Multivessel / Left main stem Coronary artery disease Pro ESC Congress 2010, 28 August 1 September Stockholm
More informationLong-Term Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents for Coronary Revascularization
Journal of the American College of Cardiology Vol. 57, No. 21, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.023
More informationSurgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome
Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome Chris C. Cook, MD Associate Professor of Surgery Director, CT Residency Program, WVU ACOI 10/17/18 No Disclosures
More informationDEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.
DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea. In-stent restenosis (ISR) Remains important issue even in the
More informationNine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large coronary vessel lesions
Journal of Geriatric Cardiology (2017) 14: 35 41 2017 JGC All rights reserved; www.jgc301.com Research Article Open Access Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large
More informationVCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital
VCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital Complex PCI: Multivessel Disease George W. Vetrovec, MD. Kimmerling Chair of Cardiology VCU Pauley Heart Center Virginia
More informationAPPENDIX F: CASE REPORT FORM
APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more
More informationPercutaneous Intervention of Unprotected Left Main Disease
Percutaneous Intervention of Unprotected Left Main Disease Technical feasibility and Clinical outcomes Seung-Jung Park, MD, PhD, FACC Professor of Internal Medicine Asan Medical Center, Seoul, Korea Unprotected
More informationClinical Trial Synopsis TL-OPI-516, NCT#
Clinical Trial Synopsis, NCT#00225277 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus
More informationCOMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands
COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands TCTAP 2010 Seoul, Korea Disclosures Research Foundation of the Cardiology Department has received unrestricted research grants from:
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationISAR-LEFT MAIN 2 Randomized Trial. Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli, MD Klinikum der Universitaet Munich Deutsches
More informationTRIAS HR Pilot Study
Late Breaking Clinical Trials TCT, October 22 nd 27, Washington, USA TRIAS HR Pilot Study RCT comparing Genous EPC capturing stent with Taxus Paclitaxel eluting stent Robbert J de Winter MD PhD FESC Academic
More informationIs it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany
Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany The demographic issue Life expectancy is increasing Patients are getting
More information